7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

RayzeBio Inc
(NASDAQ:RYZB) 

RYZB stock logo

RayzeBio is a clinical-stage radiopharmaceutical therapeutics (“RPT”) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs.

Founded: 2020
CEO: Dr. Kenneth Song  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
RayzeBio Op Cashflow Per Share ttm
202312 202401 202402 202403 202404 -2.62-2.24-1.87-1.49-1.12-0.75-0.370
RayzeBio Free Cashflow Per Share ttm
202312 202401 202402 202403 202404 -3.85-3.3-2.75-2.2-1.65-1.1-0.550
RayzeBio Cash Per Share ttm
202312 202401 202402 202403 202404 05.0110.0215.0320.0425.0530.0735.08
RayzeBio (GAAP) P/E ratio ttm
202312 202401 202402 202403 202404 -18.04-15.46-12.89-10.31-7.73-5.15-2.580
RayzeBio P/B ratio ttm
202312 202401 202402 202403 202404 00.240.480.720.961.191.431.67
No extra charts and metrics for this ticker.